Bayer's Courtroom Docket and Ohio Blueprint Move on Separate Schedules

Bayer faces an open Monsanto negligence claim, a Kerendia filing under FDA review, and a $2.2 billion Ohio plant not due until 2031.

Bayer investors are tracking two clocks that tick at very different speeds. One measures a courtroom in Missouri, where testimony is unfolding week by week. The other counts down to a factory in Ohio that will not produce a single pill until 2031. Between them sits a quarterly report due on November 3 — the only near-term event capable of settling what the other two cannot.

A Mixed Ruling, Not a Clean Win

On October 7, a US federal judge allowed a lawsuit against Monsanto to proceed in part. According to media reports, the failure-to-warn claim was dismissed, while a negligence claim was not fully precluded. That distinction matters more than any headline casting the outcome as victory or defeat. Bayer's exposure is now split: one avenue of the case is closed off, another remains open. An ongoing claim is not a finding of liability, and the survival of a single cause of action establishes nothing about who ultimately prevails.

The legal picture gained another layer on Friday, when a plaintiff testified in a Missouri proceeding that the herbicide had come into contact with her skin during extended gardening. The case, per media coverage, involves claims against Bayer subsidiary Monsanto. Her statement is testimony — evidence offered by a party — not a judicial determination of responsibility. For anyone weighing Bayer's litigation risk, the gap between what witnesses say and what courts decide is the whole ballgame.

Pharma's Longer Arc

Against that backdrop, Bayer's pharmaceutical division keeps building. The FDA has accepted the company's supplemental application for Kerendia, whose active ingredient is finerenone, covering adults with chronic kidney disease who do not have diabetes. The filing rests on data from the Phase III FIND-CKD trial. Acceptance for review is a procedural step, not an approval — no marketing authorization exists yet for this additional patient group.

The company also named Dr. Christoph Koenen as Chief Medical Officer on October 1. He will steer the medical and scientific strategy of the pharma division, placing the appointment squarely in the area where Bayer is pushing for further development milestones.

Roughly two weeks ago, Bayer unveiled a USD 2.2 billion investment in a new pharmaceutical production site in New Albany, Ohio. The first module is slated to come online in 2031, the second in 2034. The project is expected to generate around 600 permanent positions and some 1,500 construction jobs. This is a description of future capacity, not a completed expansion — a distinction that separates strategic intent from delivered output.

The Quarter That Has to Answer

Short-term expectations carry their own caution flag. JPMorgan kept Bayer at "Overweight" with a price target of EUR 61 about two weeks ago, but analyst Richard Vosser warned that early estimates for the third quarter are likely too optimistic. His reasoning centered on timing effects in the agricultural business, while he saw little change to full-year forecasts. The call neatly separates a single quarter's potential drag from the longer earnings trajectory.

Bayer reports third-quarter 2026 results on November 3. The figures land at 07:30 CET, with the earnings call following at 14:00 CET. That release — not the Missouri testimony, not the Ohio groundbreaking — is where the near-term story gets tested.

Until then, each development answers a different question. The Roundup proceedings speak to legal risk. The finerenone filing and the New Albany plans speak to the pharma pipeline's horizon. Progress on one front does nothing to retire the open claims on the other.